News

ascopubs.org21d
Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group
Abbreviations: MPNST, malignant peripheral nerve sheath tumor; ID, identification number; NF1, neurofibromatosis type 1; M, male; DFD, dead from disease; F, female ...
Pharmabiz15h
EMA committee recommends marketing approval for SpringWorks’ mirdametinib to treat adult & paediatric patients with NF1-PN
EMA committee recommends marketing approval for SpringWorks’ mirdametinib to treat adult & paediatric patients with NF1-PN: Stamford, Connecticut Tuesday, May 27, 2025, 12:00 Hr ...
Kauppalehti4d
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.
Finanznachrichten4d
SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
1, 2 Patients with NF1 have approximately a 30 to 50% lifetime risk of developing plexiform neurofibromas, which are tumors that grow in an infiltrative pattern along the peripheral nerve sheath ...
Neurofibromatosis Type 1 Market Set To Witness Significant Growth During The Study Period (2020–2034) Driven By Advances In Treatment | Delveinsight
The neurofibromatosis type 1 market remains niche, but awareness campaigns, increased diagnoses, and treatment adoption, along with ongoing clinical ...
manilatimes4d
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
As of the data cutoff date of January 5, 2025, 54 patients with advanced ACC, malignant peripheral nerve sheath tumor (MPNST), liposarcoma (LPS), biliary-tract cancer (BTC) and other tumors were ...
TMCnet6d
Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...
Multiple Sclerosis News Today11d
Increasing frailty in RRMS patients linked to higher IL-6 levels: Study
The signaling molecule IL-6, involved in inflammation, is associated with increasing frailty in relapsing-remitting MS, a ...
Frontiers6d
Clinical benefits of immune checkpoint inhibitors for malignant peripheral nerve sheath tumors with NF2 mutation: a case report
Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China ...
Frontiers27d
Clinical Benefit of Immune checkpoint inhibitor for malignant peripheral nerve sheath tumors with NF2 mutation: a case report
Background: Malignant peripheral nerve sheath tumors (MPNSTs), which arise from peripheral nerves or cells associated with nerve sheaths, are uncommon and biologically aggressive sarcomas.Currently, ...
SciELO12d
Intraosseous schwannoma of mandibular symphysis: case report
Schwannoma (neurilemmoma) is a benign neoplasm originated from the neural sheath and occurring most frequently in the ... representing less than 1% of the benign primary bone tumors (6). The most ...
verywellhealth6d
Treating Neurofibromatosis Type 1, a Nervous System Disorder
Chemical or radiation treatments may be used to reduce the size of tumors, especially if they grow unpredictably and give rise to malignant (meaning cancerous) peripheral nerve sheath tumors (MPNSTs) ...